TGM2, Abcam, ab109121

Our team performed a comprehensive review of the scientific literature to identify studies using antibodies against human protein-glutamine gamma-glutamyltransferase 2 (TGM2), followed by extraction and evaluation of available data according to pAbmAbs rating criteria.

YCharOS conducted a systematic head-to-head comparison of 17 commercially available antibodies against TGM2 across multiple applications.

Antibodies were tested by WB using lysates (40 µg protein) from A549 WT (ab275463) and TGM2 KO (ab261876) cells. These cell lines were also used for IF. In addition, antibodies were evaluated by IP using A549 WT lysate (1 mg protein). All experiments were performed according to YCharOS standard protocols (see reference).

In WB (1:1000 antibody dilution), ab109121 detected a weak band at the predicted size (~77 kDa) in WT A549 cell lysate, with no corresponding band in TGM2 KO lysate. Additionally, a band of lower molecular weight was observed in both cell lysates, most intense in the TGM2 KO sample.

In IP, the antibody (2 µg) did not enrich TGM2 upon precipitation. TGM2 levels in the starting material, unbound fraction, and precipitate were assessed by WB using the TGM2-specific antibody A21184 from ABclonal (1:10.000).

In IF, the antibody (1:1000 dilution) failed to produce a TGM2-specific staining in A549 cells.

We highly encourage other scientists to share their observations.